Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit
Bionoid Pharma (OTC PINK:BINP) has announced the completion of its audited financial statements for fiscal year 2024. The audit was performed by Aloba Awomolo & Partners LLP, Chartered Professional Accountants. CEO Wayne Cockburn highlighted this as a significant milestone for the company, positioning them for their next phase of corporate growth strategy.
The company plans to use this audit completion as a stepping stone toward their application to uplist to a more senior stock exchange. The audited financial statements will be made available on the OTC Markets website, demonstrating the company's commitment to transparency and corporate governance.
Bionoid Pharma (OTC PINK:BINP) ha annunciato il completamento dei suoi bilanci finanziari auditati per l'anno fiscale 2024. L'audit è stato effettuato da Aloba Awomolo & Partners LLP, Commercialisti Professionisti Abilitati. Il CEO Wayne Cockburn ha evidenziato questo come un traguardo significativo per l'azienda, posizionandola per la sua prossima fase della strategia di crescita aziendale.
L'azienda prevede di utilizzare il completamento di questo audit come trampolino di lancio per la sua richiesta di passaggio a una borsa valori di grado superiore. I bilanci finanziari auditati saranno resi disponibili sul sito web di OTC Markets, dimostrando l'impegno dell'azienda verso la trasparenza e la governance aziendale.
Bionoid Pharma (OTC PINK:BINP) ha anunciado la finalización de sus estados financieros auditados para el año fiscal 2024. La auditoría fue realizada por Aloba Awomolo & Partners LLP, Contadores Públicos Certificados. El CEO Wayne Cockburn destacó esto como un hito significativo para la empresa, posicionándola para su próxima fase de estrategia de crecimiento corporativo.
La empresa planea utilizar esta finalización de auditoría como un trampolín hacia su solicitud para ser listada en una bolsa de valores de mayor categoría. Los estados financieros auditados estarán disponibles en el sitio web de OTC Markets, demostrando el compromiso de la empresa con la transparencia y la gobernanza corporativa.
Bionoid Pharma (OTC PINK:BINP)는 2024 회계연도에 대한 감사 재무제표의 완료를 발표했습니다. 감사는 Aloba Awomolo & Partners LLP, 공인 회계사에 의해 수행되었습니다. CEO Wayne Cockburn은 이를 회사에 중요한 이정표로 강조하며, 다음 단계의 기업 성장 전략을 위한 기반을 마련했다고 언급했습니다.
회사는 이 감사 완료를 더 높은 수준의 주식 거래소로의 상장 신청을 위한 디딤돌로 활용할 계획입니다. 감사된 재무제표는 OTC Markets 웹사이트에 공개되어, 회사의 투명성과 기업 거버넌스에 대한 의지를 보여줄 것입니다.
Bionoid Pharma (OTC PINK:BINP) a annoncé l'achèvement de ses états financiers audités pour l'exercice 2024. L'audit a été réalisé par Aloba Awomolo & Partners LLP, Experts-Comptables Agréés. Le PDG Wayne Cockburn a souligné cela comme une étape significative pour l'entreprise, la positionnant pour sa prochaine phase de stratégie de croissance d'entreprise.
L'entreprise prévoit d'utiliser cet achèvement d'audit comme tremplin pour sa demande de passage à une bourse de valeurs plus senior. Les états financiers audités seront disponibles sur le site Web des OTC Markets, démontrant l'engagement de l'entreprise envers la transparence et la gouvernance d'entreprise.
Bionoid Pharma (OTC PINK:BINP) hat den Abschluss seiner geprüften Finanzberichte für das Geschäftsjahr 2024 bekannt gegeben. Die Prüfung wurde von Aloba Awomolo & Partners LLP, Wirtschaftsprüfern, durchgeführt. CEO Wayne Cockburn hob dies als einen bedeutenden Meilenstein für das Unternehmen hervor und positionierte es für die nächste Phase der Unternehmenswachstumsstrategie.
Das Unternehmen plant, diesen Abschluss der Prüfung als Sprungbrett für seinen Antrag auf eine Listung an einer höherwertigen Börse zu nutzen. Die geprüften Finanzberichte werden auf der Website der OTC Markets verfügbar sein, was das Engagement des Unternehmens für Transparenz und Unternehmensführung demonstriert.
- Successful completion of 2024 financial audit
- Progress toward potential uplisting to senior exchange
- Enhanced financial transparency and governance
- Currently trading on OTC Pink market, indicating lower tier listing
NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its audited financial statements for the fiscal year ended December 31, 2024. The audit was conducted by Aloba Awomolo & Partners LLP, Chartered Professional Accountants, who were engaged earlier this year as Bionoid's external auditor.
"This marks an important milestone for Bionoid," said Wayne Cockburn, CEO of Bionoid Pharma. "Completing our 2024 audit puts us in a strong position as we now shift our focus toward the next phase of our corporate growth strategy - including the work required to advance our application to uplist to a more senior stock exchange. We remain committed to transparency, strong governance, and delivering long-term value to our shareholders."
The audited financial statements will be filed on https://www.otcmarkets.com/.
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.
AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.
Stay Connected:
Website: | |
OTC Markets: | BINP |
X (formerly Twitter): | @BionoidPharminc |
For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: bionoidpharma@gmail.com
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the significance of Bionoid Pharma (BINP) completing its 2024 financial audit?
Which accounting firm conducted Bionoid Pharma's (BINP) 2024 financial audit?
Where can investors access Bionoid Pharma's (BINP) 2024 audited financial statements?
What are Bionoid Pharma's (BINP) plans following the 2024 audit completion?
